Document is current
Any future updates will be listed below
-
Authors
Hagiwara, Hirotaka
Takano, Tomotsugu
Ogata, Hiroaki
Tsubouchi, Kazuya
Ichiki, Katsuyuki
Takata, Shohei
Ishii, Hiroshi
Kitasato, Yasuhiko
Zaizen, Yoshiaki
Yatera, Kazuhiro
Kawasaki, Masayuki
Fujita, Masaki
Yoshida, Makoto
Maeyama, Takashige
Mashimoto, Ayano
Furuyama, Kazuto
Torii, Ryo
Suzuki, Kunihiro
Mizuta, Yuichi
Tobino, Kazunori
Harada, Eiji
Kiyomi, Fumiaki
Yabuuchi, Hidetake
Nakanishi, Yoichi
Okamoto, Isamu
-
Funding
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science, and Technology; the broad-area, network-based Project to Drive Clinical Research at Kyushu University Hospital
Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare, Japan
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 10 September 2025
First Online: 14 October 2025
Declarations
:
: This prospective, multicenter, observational study was approved by the Institutional Review Board of Kyushu University (#25–135, August 23, 2013; #555-00, August 27, 2013) and by the institutional review boards of all participating hospitals. Written informed consent was obtained from all patients. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research. Clinical trial number: not applicable. The study was conducted in accordance with the principles of the Declaration of Helsinki.
: Not applicable since there are no details on individuals reported within the manuscript.
: KTsubouchi has received personal fees from Boehringer Ingelheim Japan Inc. ST has received personal fees from AstraZeneca KK, Boehringer Ingelheim Japan Inc, and Novartis Pharma KK. KY has received personal fees from Boehringer Ingelheim Japan Inc and GlaxoSmithKline K.K. YN has received personal fees from Gaia Biomedicine and Delta-Fly Pharma. IO has received personal fees from Daiichi Sankyo, Chugai Pharma, Lilly, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol-Myers Squibb, MSD Oncology, AstraZeneca KK, Boehringer Ingelheim Japan Inc, Takeda Pharmaceutical Company Limited, and Novartis Pharma K.K.
